Crescendo to participate in upcoming investor conferences - June 01, 2021
CAMBRIDGE, England--(BUSINESS WIRE)-- Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that senior members of the executive team will be participating at the following three conferences to meet investors to discuss the Company’s business strategy, technology, discovery platform and development programmes.
- Kempen Life Sciences Crossover Conference (Virtual), 16 June 2021
- JMP Securities Life Sciences Conference (Virtual), 17 June 2021
Presentation at 10:00 am EDT, 3:00 pm BST
- BioTrinity (Virtual & London, UK), 21 June 2021
Presentation at 2:20 pm BST
If you are interested in meeting the team at these events, please contact the Company via email at firstname.lastname@example.org.
Please refer to individual conference websites for further information and updated schedules.
About Crescendo Biologics
Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics.
Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody® for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anticancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours.
The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches. Humabody®-based formats can also be applied across a range of non-cancer indications.
Beyond Crescendo’s proprietary pipeline, the Company has a global, multi-target discovery and development collaboration with Takeda; a clinical development partnership with Cancer Research UK; and an exclusive, worldwide licensing agreement with Zai Lab, the product candidate of which is in a Phase 1 clinical trial.
Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210601005045/en/
Source: Crescendo Biologics Ltd
View this news release online at: